Chad Groer

Chad Groer

Auto-generated profile, based on publicly available information

Chad Groer

Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CGChad E. Groer
Chad E. Groer
CSCullen L. Schmid
Cullen L. Schmid
AJAlex M. Jaeger
Alex M. Jaeger
LBLaura M. Bohn
Laura M. Bohn
Morphine and other opiates mediate their effects through activation of the μ-opioid receptor (MOR), and regulation of the MOR has been shown to critically affect receptor responsiveness. Activation of the MOR results in receptor phosphorylation, β-arrestin recruitment, and internalization. This classical regulatory process can differ, depending on the ligand occupying the receptor. There are two forms of β-arrestin, β-arrestin1 and β-arrestin2 (also known as arrestin2 and arrestin3, respectively); however, most studies have focused on the consequences of recruiting β-arrestin2 specifically. In this study, we examine the different contributions of β-arrestin1- and β-arrestin2-mediated regulation of the MOR by comparing MOR agonists in cells that lack expression of individual or both β-arrestins. Here we show that morphine only recruits β-arrestin2, whereas the MOR-selective enkephalin [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO), recruits either β-arrestin. We show that β-arrestins are required for receptor internalization and that only β-arrestin2 can rescue morphine-induced MOR internalization, whereas either β-arrestin can rescue DAMGO-induced MOR internalization. DAMGO activation of the receptor promotes MOR ubiquitination over time. Interestingly, β-arrestin1 proves to be critical for MOR ubiquitination as modification does not occur in the absence of β-arrestin1 nor when morphine occupies the receptor. Moreover, the selective interactions between the MOR and β-arrestin1 facilitate receptor dephosphorylation, which may play a role in the resensitization of the MOR and thereby contribute to overall development of opioid tolerance.

13 September 2020 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
SHSebastian G. Huayamares
Sebastian G. Huayamares
JSJimmy Y. Song
Jimmy Y. Song
AHAric Huang
Aric Huang
SCSamuel R. Crowl
Samuel R. Crowl
CGChad E. Groer
Chad E. Groer
CBCory Berkland
Cory Berkland

8 October 2018 in Case Reports in Veterinary Medicine
Verified
Journal Article
Open access
PDF file
SCShuang Cai
Shuang Cai
TZTi Zhang
Ti Zhang
CGChad Groer
Chad Groer
MFMelanie Forrest
Melanie Forrest
DADaniel Aires
Daniel Aires
MFM. Laird Forrest
M. Laird Forrest
This case report documents the diagnosis, treatment, and outcome of a nonresectable oral squamous cell carcinoma in a dog with initial poor prognosis. An approximately 4-year-old female Staffordshire Bull Terrier presented with a large mass on the front of lower jaw which was diagnosed as oral papillary squamous cell carcinoma by histopathology. CT scans revealed invasion of the cancer to the frenulum of the tongue. The mass was inoperable due to location, expansiveness, and metastatic lymph nodes. The dog received 4 treatments of intralesional hyaluronan-platinum conjugates (HylaPlat™, HylaPharm LLC, Lawrence, Kansas) at 3-week intervals. Clinical chemistry and complete blood count were performed one week after each treatment and results were within normal limits. Complications included bleeding due to tumor tissue sloughing, as well as a single seizure due to unknown causes. Upon completion of chemotherapy, CT showed that the mass had regressed and was no longer invading the lingual frenulum, and multiple lymph nodes were free of metastasis. The mass thus became resectable and the dog successfully underwent rostral bilateral mandibulectomy. Over one year after chemotherapy and surgery, the cancer remains in complete remission.

17 February 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
YZYilue Zhang
Yilue Zhang
MBMaribel Espinoza Ballesteros
Maribel Espinoza Ballesteros
CGChad Groer
Chad Groer
DRDavid S. Richards
David S. Richards
MFM. Laird Forrest
M. Laird Forrest
Evaluation of pharmacokinetics is a cornerstone in the developability assessment of therapeutic monoclonal antibodies (mAbs). For accurate evaluation of mAbs' concentration-time profile, administered mAbs should be isolated from the interfering host proteins in serum samples. While there are multiple approaches to purify and quantify the administered mAb, they are limited by drawbacks such as low specificity, relatively-large plasma volume requirements, and tedious procedures for sample preparation and analysis. Here, we present an immunoprecipitation assay that uses a highly specific anti-human IgG1 antibody coupled with magnetic beads (R10-coupled Dynabeads) for the purification of adalimumab and forced-oxidized variants. The specificity and binding capacity of R10-coupled Dynabeads were confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. To demonstrate the wide applicability of this method, two different stressed variants involving mixtures with rat proteins were examined which are chemical oxidation stress and physical agitation stress. The results showed comparable recovery of native adalimumab and oxidized variants from in vitro and in vivo rat proteins mixture. R10-coupled Dynabeads also recovered aggregated species, but the method itself induced more aggregate formation as evident from analysis by dynamic light scattering and background membrane imaging. Pharmacokinetic evaluation showed a typical concentration-time profile for native adalimumab which is broadly consistent with reported profiles. This method can provide an efficient and highly-specific recovery of human IgG1 and degradation products from preclinical biological samples, provided that the epitope recognized by the used anti-human IgG antibody is retained and accessible. Furthermore, the integration of R10-coupled Dynabeads purification, Trypsin/Lys-C digestion, and QToF LC-MS/MS analysis enabled efficient capture of the oxidized species generated by AAPH and H2O2 (% sequence coverage ≥ 90%). Accordingly, this combined workflow can be applied to study in vivo modifications of therapeutic proteins (e.g. oxidation, deamidation) after exposure to an anatomical environment.

28 November 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
MAMoustafa M. Abdelaziz
Moustafa M. Abdelaziz
CGChad Groer
Chad Groer
JWJack D. Weiner
Jack D. Weiner
SKSuresh E. Kurhade
Suresh E. Kurhade
PRPatrick Ross
Patrick Ross
MFM. Laird Forrest
M. Laird Forrest